Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
Chimeric antigen receptor (CAR)-T cell therapy emerges as a new treatment for refractory or relapsed (r/r) B-cell non-Hodgkin lymphoma (B-NHL); however, the overall response rate (ORR) of which in the B-NHL patients is much lower compared to the patients with r/r B acute lymphoblastic leukemia (B-AL...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.640166/full |
| _version_ | 1818721509725700096 |
|---|---|
| author | Yuan Meng Biping Deng Luan Rong Chuo Li Weiliang Song Zhuojun Ling Jinlong Xu Jiajia Duan Zelin Wang Alex H. Chang Xiaoming Feng Xiujuan Xiong Xiaoli Chen Jing Pan Jing Pan |
| author_facet | Yuan Meng Biping Deng Luan Rong Chuo Li Weiliang Song Zhuojun Ling Jinlong Xu Jiajia Duan Zelin Wang Alex H. Chang Xiaoming Feng Xiujuan Xiong Xiaoli Chen Jing Pan Jing Pan |
| author_sort | Yuan Meng |
| collection | DOAJ |
| description | Chimeric antigen receptor (CAR)-T cell therapy emerges as a new treatment for refractory or relapsed (r/r) B-cell non-Hodgkin lymphoma (B-NHL); however, the overall response rate (ORR) of which in the B-NHL patients is much lower compared to the patients with r/r B acute lymphoblastic leukemia (B-ALL). We previously confirmed that sequential infusions of CD20 and CD22 CAR-T cells significantly improved the prognosis of the B-NHL patients, while some advanced patients still progressed to death during these CAR-T cell treatments. In this study, we showed that timely sequential administration of the second CAR-T cells could enhance expansion of prior CAR-T cells with stronger tumor-killing capacity in vitro and in vivo. We further conducted compassionate treatments on two advanced B-NHL patients with short-interval sequential infusions of CD19/22/20 CAR-T cells. Disease progression was observed in both patients after primary CAR-T cell infusion but robust re-expansion of prior CAR-T cells and anti-tumor effects was induced by infusion of a secondary CAR-T cells. These results indicate sequential infusions of CAR-T cells with a short interval may improve therapeutic efficacy in the B-NHL patients by promoting expansion of prior CAR-T cells. |
| first_indexed | 2024-12-17T20:39:52Z |
| format | Article |
| id | doaj.art-0ebebbceff784e0699861764da4a5d6f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-17T20:39:52Z |
| publishDate | 2021-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-0ebebbceff784e0699861764da4a5d6f2022-12-21T21:33:21ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-06-011110.3389/fonc.2021.640166640166Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHLYuan Meng0Biping Deng1Luan Rong2Chuo Li3Weiliang Song4Zhuojun Ling5Jinlong Xu6Jiajia Duan7Zelin Wang8Alex H. Chang9Xiaoming Feng10Xiujuan Xiong11Xiaoli Chen12Jing Pan13Jing Pan14State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, ChinaCytology Laboratory, Beijing Boren Hospital, Beijing, ChinaCytology Laboratory, Beijing Boren Hospital, Beijing, ChinaState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, ChinaDepartment of Hematology, Beijing Boren Hospital, Beijing, ChinaDepartment of Hematology, Beijing Boren Hospital, Beijing, ChinaDepartment of Hematology, Beijing Boren Hospital, Beijing, ChinaDepartment of Hematology, Beijing Boren Hospital, Beijing, ChinaDepartment of Hematology, Beijing Boren Hospital, Beijing, ChinaClinical Translational Research Center, Tongji University School of Medicine, Shanghai, ChinaState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, ChinaDepartment of Pathology, Basic Medical College of Nanchang University, Nanchang, ChinaGanzhou Key Laboratory of Molecular Medicine, the Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, ChinaState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, ChinaState Key Laboratory of Experimental Hematology, Boren Clinical Translational Center, Department of Hematology, Beijing Boren Hospital, Beijing, ChinaChimeric antigen receptor (CAR)-T cell therapy emerges as a new treatment for refractory or relapsed (r/r) B-cell non-Hodgkin lymphoma (B-NHL); however, the overall response rate (ORR) of which in the B-NHL patients is much lower compared to the patients with r/r B acute lymphoblastic leukemia (B-ALL). We previously confirmed that sequential infusions of CD20 and CD22 CAR-T cells significantly improved the prognosis of the B-NHL patients, while some advanced patients still progressed to death during these CAR-T cell treatments. In this study, we showed that timely sequential administration of the second CAR-T cells could enhance expansion of prior CAR-T cells with stronger tumor-killing capacity in vitro and in vivo. We further conducted compassionate treatments on two advanced B-NHL patients with short-interval sequential infusions of CD19/22/20 CAR-T cells. Disease progression was observed in both patients after primary CAR-T cell infusion but robust re-expansion of prior CAR-T cells and anti-tumor effects was induced by infusion of a secondary CAR-T cells. These results indicate sequential infusions of CAR-T cells with a short interval may improve therapeutic efficacy in the B-NHL patients by promoting expansion of prior CAR-T cells.https://www.frontiersin.org/articles/10.3389/fonc.2021.640166/fullB-NHLCAR-TCD19CD22CD20 |
| spellingShingle | Yuan Meng Biping Deng Luan Rong Chuo Li Weiliang Song Zhuojun Ling Jinlong Xu Jiajia Duan Zelin Wang Alex H. Chang Xiaoming Feng Xiujuan Xiong Xiaoli Chen Jing Pan Jing Pan Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL Frontiers in Oncology B-NHL CAR-T CD19 CD22 CD20 |
| title | Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL |
| title_full | Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL |
| title_fullStr | Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL |
| title_full_unstemmed | Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL |
| title_short | Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL |
| title_sort | short interval sequential car t cell infusion may enhance prior car t cell expansion to augment anti lymphoma response in b nhl |
| topic | B-NHL CAR-T CD19 CD22 CD20 |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.640166/full |
| work_keys_str_mv | AT yuanmeng shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl AT bipingdeng shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl AT luanrong shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl AT chuoli shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl AT weiliangsong shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl AT zhuojunling shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl AT jinlongxu shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl AT jiajiaduan shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl AT zelinwang shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl AT alexhchang shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl AT xiaomingfeng shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl AT xiujuanxiong shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl AT xiaolichen shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl AT jingpan shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl AT jingpan shortintervalsequentialcartcellinfusionmayenhancepriorcartcellexpansiontoaugmentantilymphomaresponseinbnhl |